Stem Cell-Derived Gene Expression Scores Predict Survival and Blastic Transformation in Myelofibrosis

Author:

Medeiros Jessie J.F.ORCID,Zeng Andy G.X.ORCID,Chan-Seng-Yue MichelleORCID,Woo TristanORCID,Bansal Suraj,Kim Hyerin,McLeod Jessica L.,Arruda Andrea,Tsui Hubert,Claudio Jaime O.,Maze DawnORCID,Sibai Hassan,Minden Mark D.,Kennedy James A.,Wang Jean C.Y.ORCID,Dick John E.ORCID,Gupta Vikas

Abstract

ABSTRACTPurposeMyelofibrosis (MF) is the most severe myeloproliferative neoplasm (MPN) where there remains a need for improved risk stratification methods to better inform patient management. Since MF is a stem cell driven disease and stem cell informed transcriptomic information has been shown to be prognostic across other clinical settings we sought to use this information to generate novel transcriptomic-based risk stratification models that could complement current approaches.Patients and MethodsWe identified 358 MF patients from the MPN registry at the Princess Margaret Cancer Centre (ClinicalTrials.govIdentifier:NCT02760238) from whom peripheral blood mononuclear cells were collected and clinical data was available. We randomly split our cohort into a 250-patient training set and a 108-patient test set to train and validate prognostic models, respectively.ResultsWithin the training set we used repeated nested cross validation together with LASSO regression from various starting gene sets and found that the best prognostic models were consistently derived from transcriptomic variation among MF stem cells. From this gene set we trained our final model, a 24-gene weighted expression score (termed, MPN24) that is prognostic for overall survival. Patients were classified as MPN24-High or MPN24-Low risk depending on whether their scores were above or below the within cohort median defined in the training set. The prognostic power of MPN24 was validated in the test set patients with stark differences in survival outcomes for MPN24-High (5-year survival rate = 21% [95% CI 9%-52%]) and MPN24-Low risk patients (5-year survival rate = 71% [95% CI 57-88%]) patients, resulting in a HR of 5.3 (95% CI: 2.6-10.5; p=2.08e-6). MPN24 captures unique prognostic information to current risk stratification models such as DIPSS, MIPSS70 and the Genomic-Personalized Risk scores. Therefore, we present a novel 3-tier risk stratification approach that integrates DIPSS and MPN24 to more effectively risk stratify MF patients, particularly via up or downscaling patient risk within the DIPSS-Intermediate-1/2 categories. In this integrated model patients were classified as Integrated-Low, Integrated-Intermediate or Integrated-High, and experienced 5-year survival rates of 88.2% [95% CI 77.9% - 99.9%], 39.3% [95% CI 19.9% - 77.7%], and 10.8% [95% CI 2.1% - 55.8%], respectively (likelihood ratio test p = 1e-8). Finally, from MPN24 genes we derived a 13-gene subsignature (termed, MPN13) from the training set patients that was validated to predict time-to-transformation in the test set patients when classified as MPN13-High or Low relative to the 80th percentile of MPN13 scores from the training set (p=0.0047). In the test set, MPN13-High and MPN13-Low patients experienced 3-year cumulative incidences of transformation of 5.2% [95% CI 0.2%-10.2%] and 28.6% [95% CI 3.1%-54.0%] respectively, after adjusting for death as a competing risk.ConclusionsTranscriptomic information informed by MF stem cells offer novel and unique prognostic potential in MF that significantly complements current approaches. Future work will be needed to validate the robustness of the approach in external cohorts and identify how patient management can be optimized with these novel transcriptomic biomarkers.

Publisher

Cold Spring Harbor Laboratory

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3